{"groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 milligrams (mg) (absolute dose) on Days 1 and 8 of every 3-week cycle.\n\nPemetrexed: 500 mg/square meter (mg/m2) intravenous (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles.","id":"FG000","title":"Necitumumab + Pemetrexed + Cisplatin"},{"description":"Pemetrexed + Cisplatin\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles.","id":"FG001","title":"Pemetrexed + Cisplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"39"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}],"type":"New Anti-Cancer Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Medical Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"19"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Global Study End"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Sponsor's Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"315"},{"groupId":"FG001","numSubjects":"318"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"304"},{"groupId":"FG001","numSubjects":"312"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"236"},{"groupId":"FG001","numSubjects":"246"}],"type":"Death Due to Any Cause"},{"achievements":[{"groupId":"FG000","numSubjects":"236"},{"groupId":"FG001","numSubjects":"246"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"72"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers included participants who died from any cause and participants who were alive and on study at conclusion however were off treatment."}